Probiotics

Updated June 3, 2026

A specific probiotic strain, matched to a specific problem, can do concrete work. Saccharomyces boulardii cuts antibiotic associated diarrhea risk in randomized trials. Lactobacillus rhamnosus GG shortens acute pediatric diarrhea. VSL#3 and Visbiome multi strain formulas keep pouchitis in remission after colectomy. These are real outcomes from real trials, and they tell you where the category earns its keep. The catch is that the unit of evidence is the strain, written as genus, species, then a strain code, like Lactobacillus rhamnosus GG or Bifidobacterium longum 35624. Marketing copy that names only "Lactobacillus acidophilus" or "ten powerful strains" is closer to advertising a drug class than a drug.

What these organisms actually do runs along a few established axes. The first is short chain fatty acid output. Resident and transient bacteria ferment fibers and resistant starches in the colon into butyrate, propionate, and acetate. Butyrate is the preferred fuel of colonocytes, supports tight junction proteins like ZO-1 and occludin that hold the intestinal barrier shut, and acts as a histone deacetylase inhibitor with downstream effects on inflammatory gene expression. Propionate signals through free fatty acid receptors and nudges hepatic glucose handling. None of this happens without fermentable substrate, which is why probiotics on a fiber poor diet often underperform their trials.

The second axis is immune education. Roughly seventy percent of the body's immune tissue sits in the gut wall, around Peyer's patches and the lamina propria. Bifidobacterium and certain Lactobacillus species interact with dendritic cells, tilt naive T cells toward regulatory phenotypes, raise secretory IgA at the mucosal surface, and modulate IL-10 and TNF-alpha signaling. This plausibly underlies modest signals in atopic disease and the solid signals in antibiotic associated diarrhea.

The CFU number on the bottle deserves the same scrutiny. CFU means colony forming units, and the figure printed is usually what was in the capsule at manufacture, not what reaches the small intestine. Stomach acid kills the majority of unprotected live bacteria. Bile finishes off more. The gap between fifty billion CFU at the factory and what colonizes, even transiently, can be one to two orders of magnitude. A strain that survives transit at lower counts will routinely outperform a flashier label.

The strains worth knowing by name. Saccharomyces boulardii, technically a yeast rather than a bacterium, has consistent randomized trial evidence for reducing antibiotic associated diarrhea and for shortening certain acute infectious diarrheas, with pediatric data summarized in Cochrane reviews. It survives stomach acid well, partly because it is a yeast, and it is not killed by the antibiotic you are taking alongside it. Lactobacillus rhamnosus GG, the original LGG strain isolated by Gorbach and Goldin in the 1980s, has the deepest trial record of any single bacterial probiotic, with broadly positive results for antibiotic associated diarrhea, acute pediatric diarrhea, and modest signals in some IBS endpoints. Bifidobacterium longum 35624, the strain in Align, has company linked trials in IBS showing symptom improvement, though independent replication is thinner than the marketing implies.

The gut brain piece is real but narrower than the popular framing. Bacterial metabolites and cell wall components reach vagal afferents in the gut wall, and SCFAs cross into circulation with measurable effects on microglial maturation in animal models. Some strains synthesize GABA, others influence tryptophan availability for serotonin synthesis, though most serotonin sits in enterochromaffin cells rather than crossing into the brain. Bifidobacterium longum 1714 has shown small mood and anxiety signals in trials.

Multi strain math is not additive. Each strain in a multi strain product is a separate biological entity with its own evidence file. Combining ten weakly studied strains does not produce ten times the benefit; it produces a product whose net effect nobody has measured. The trials that exist on multi strain formulas, VSL#3 and its successor Visbiome being the classic example, are on those exact blends at those exact doses, used for pouchitis after colectomy. Swap a strain or change the manufacturer and you are not running the same product. There was a public dispute over precisely this when VSL#3 changed manufacturers.

Storage form is a real trade off. Refrigerated probiotics maintain higher live counts through shelf life, particularly for delicate Lactobacillus and Bifidobacterium species. Shelf stable products use freeze drying, protective coatings, and strain selection for robustness. A well formulated shelf stable product from a serious manufacturer will often outperform a refrigerated one that sat on a warm truck. Look for guaranteed CFU through expiration date rather than at manufacture, and favor brands that publish third party testing.

Who actually benefits, and how. People starting antibiotics, particularly children and older adults, have solid evidence for S. boulardii or LGG to reduce diarrhea risk; take it during the course and for a week or two after, spaced a couple of hours from the antibiotic dose. Travelers heading somewhere with high infectious diarrhea risk have moderate evidence for a few specific strains taken daily. People with IBS often get symptom relief from LGG or B. longum 35624, though the response is individual and a four to eight week trial is the honest way to find out. Patients with pouchitis after ulcerative colitis surgery have a real indication for the high dose multi strain formulas like Visbiome. Fermented foods (yogurt with live cultures, kefir, sauerkraut, kimchi) cover adjacent territory at much lower cost, and the kefir and yogurt literature for lactose digestion is genuinely strong. A prebiotic fiber source alongside, inulin, partially hydrolyzed guar gum, or a vegetable heavy diet, feeds SCFA production and is often the limiting input.

A few cautions, brief and real. People who are severely immunocompromised, have central venous catheters, or are critically ill have had rare cases of bloodstream infection from probiotic organisms, including S. boulardii fungemia. That risk is concrete for that population. Quality control across brands also varies widely, and independent lab testing has repeatedly found products that did not contain what the label claimed. This is general information, not medical advice. If you are immunocompromised, pregnant, or managing a chronic GI condition, decide with a clinician rather than the bottle.

Cards on the table: probiotics are a real category with real evidence for a few specific strains in a few specific situations. The mechanisms that drive the wins, SCFA production, barrier reinforcement, mucosal immune tuning, vagal signaling, depend on substrate, strain, and dose. Match a trial backed strain to a problem it was studied for and you get a concrete benefit. Treat the CFU race and strain count race as marketing.